Tarceva
Product Images NDC 54868-5447

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Tarceva (NDC 54868-5447). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Physicians Total Care, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image Of 25 mg Package Label (5290)

Label for Tarceva 25mg tablets distributed by Physicians Total Care, Inc. The label shows the NDC number 54868-5290-0, package count of 30 tablets, lot number placeholder 0000, and an expiration date of 01/60. Manufacturer listed as Schwarz Pharma, Seymour, IN.*

FDA Label Image

Image Of 150 mg Package Label (5447)

Packaging label for Tarceva 150 mg tablets, distributed by Physicians Total Care, Inc. in Tulsa, OK. The label includes the NDC 54868-5447-0 and indicates a quantity of 30 tablets. It also shows a lot number placeholder and an expiration date placeholder, along with a barcode and manufacturer information noting Schwarz Pharma, Seymour, IN 47274.*

FDA Label Image

Image Of 100 mg Package Label (5474)

Packaging label for Tarceva 100 mg tablets, distributed by Physicians Total Care, Inc. The label shows the NDC 54868-5474-0, package size of 30 tablets, lot number 0000, and an expiration date of 01/60. Manufactured by Schwarz Pharma in Seymour, IN.*

FDA Label Image

Image Of Chemical Formula (Tarceva 01)

Chemical structure of the active ingredient in Tarceva. The image shows a labeled molecular diagram including a quinazoline core with attached methoxy and other side groups, as well as a hydrochloride (HCl) component.*

FDA Label Image

Image Of Figure 1 (Tarceva 02)

A Kaplan-Meier survival curve graph comparing overall survival of patients treated with Tarceva versus placebo over time in months. The graph shows survival probability on the y-axis and survival time in months on the x-axis, illustrating higher survival probability for Tarceva (N=488) with a median survival of 6.7 months compared to placebo (N=243) with a median of 4.7 months. Hazard ratio is 0.73 with p-value less than 0.001.*

FDA Label Image

Image Of Figure 2 (Tarceva 03)

A Kaplan-Meier survival curve chart comparing overall survival between two groups: Tarceva (N=261) and Placebo (N=260). The x-axis shows survival time in months up to 24 months, and the y-axis shows survival probability from 0 to 1. The chart includes median survival times of 6.4 months for Tarceva and 6.0 months for Placebo, along with hazard ratio (HR) of 0.81 and a p-value of 0.028.*

FDA Label Image

Image Of Genetech Logo (Tarceva 04)

FDA Label Image

Image Of Osi Logo (Tarceva 05)

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.